U.S. patent number 8,277,384 [Application Number 12/431,469] was granted by the patent office on 2012-10-02 for system and method for in vivo measurement of biological parameters.
This patent grant is currently assigned to Ilya Fine. Invention is credited to Ilya Fine.
United States Patent |
8,277,384 |
Fine |
October 2, 2012 |
System and method for in vivo measurement of biological
parameters
Abstract
A system, method and medical tool are presented for use in
non-invasive in vivo determination of at least one desired
parameter or condition of a subject having a scattering medium in a
target region. The measurement system comprises an illuminating
system, a detection system, and a control system. The illumination
system comprises at least one light source configured for
generating partially or entirely coherent light to be applied to
the target region to cause a light response signal from the
illuminated region. The detection system comprises at least one
light detection unit configured for detecting time-dependent
fluctuations of the intensity of the light response and generating
data indicative of a dynamic light scattering (DLS) measurement.
The control system is configured and operable to receive and
analyze the data indicative of the DLS measurement to determine the
at least one desired parameter or condition, and generate output
data indicative thereof.
Inventors: |
Fine; Ilya (Rehovot,
IL) |
Assignee: |
Fine; Ilya (Rehovot,
IL)
|
Family
ID: |
39344694 |
Appl.
No.: |
12/431,469 |
Filed: |
April 28, 2009 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20090209834 A1 |
Aug 20, 2009 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
PCT/IL2007/001317 |
Oct 30, 2007 |
|
|
|
|
60855143 |
Oct 30, 2006 |
|
|
|
|
Current U.S.
Class: |
600/485; 600/481;
600/504; 600/502 |
Current CPC
Class: |
A61B
5/14551 (20130101); A61B 5/0261 (20130101); A61B
5/14532 (20130101) |
Current International
Class: |
A61B
5/02 (20060101) |
Field of
Search: |
;600/310,322,323,324,502,481,485,504 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
International Search Report and Written Opinion, mailed Jun. 4,
2008, from International Application No. PCT/IL20071001317, filed
Oct. 30, 2007. cited by other .
EPO search report of EP 07827291 national phase of
PCT/IL2007/001317 (related case in Europe)--mailed May 30, 2011.
cited by other.
|
Primary Examiner: Winakur; Eric
Parent Case Text
RELATED APPLICATIONS
This application is a Continuation of International Application No.
PCT/IL2007/001317, filed on Oct. 30, 2007, which in turn claims the
benefit under 35 USC 119(e) of U.S. Provisional Application No.
60/855,143, filed on Oct. 30, 2006, both of which are incorporated
herein by reference in their entirety.
Claims
What is claimed is:
1. A system for use in non-invasive in vivo determination of at
least one desired parameter or condition of a subject having a
scattering medium in a target region, said system comprising: (i)
an illuminating system including at least one source of partially
or entirely coherent light to be applied to the target region in
said subject to cause a light response signal from the illuminated
region; (ii) a detection system including at least one light
detection unit configured for detecting time-dependent fluctuations
of the intensity of the light response and generating data
indicative of a dynamic light scattering (DLS) measurement; (iii) a
control system configured and operable to receive and analyze the
data indicative of the DLS measurement to determine said at least
one desired parameter or condition, and generate output data
indicative thereof; and a controllably operated pressurizing
assembly configured and operable to affect a change in a blow
flow.
2. The system of claim 1, wherein the data generated by the
detection system is indicative of fluctuation dependent speckle
pattern of the light response over a predetermined frequency
interval.
3. The system of claim 2, wherein the control system is configured
and operable for analyzing the received data by using temporal
autocorrelation intensity analyzing or power spectrum
analyzing.
4. The system of claim 1, wherein said control system is configured
and operable to analyze the received data to reject low frequency
components of the received data, and process high frequency
components of the received data, thereby enabling elimination of
motion artifacts.
5. The system of claim 1, wherein said control system comprises: a
data acquisition utility responsive to the generated data coming
from said detection system; a data processing and analyzing utility
for analyzing data from said data acquisition utility and determine
the at least one hemorheological and blood chemical parameter; a
memory utility for storing coefficients required to perform
predetermined calculation by said data processing and analyzing
utility, and an external information exchange utility configured to
enable downloading of the processed information to an external user
or to display it.
6. The system of claim 5, wherein the control system comprises a
control utility associated with the pressurizing assembly.
7. The system of claim 1, configured and operable to create an
intermittent blood stasis state by applying over systolic blood
pressure to the subject, thereby enabling determination of red
blood cell (RBC) aggregation.
8. The system of claim 1, wherein said at least one light source of
the illumination system is coupled with a polarization unit
enabling to create polarized electromagnetic signal in one
preferable direction, and an entrance of at least one of detection
units of the detection system is coupled with a polarization unit
such that the polarization unit enables only certain direction of
pre-selected polarized radiation to be detected.
9. An optical method for use in determining in vivo hemorheological
chemical and physiological parameters of a subject, the method
comprising: (i) applying partially or entirely coherent light to a
target region in said subject to cause a light response signal from
the target region; (ii) detecting fluctuation dependent speckle
pattern of the light response signal over a predetermined frequency
interval, and generating data indicative thereof, (iii) processing
the detected data by using temporal autocorrelation intensity
analyzing or power spectrum analyzing; and, (iv) determining blood
viscosity of said subject from the time-fluctuation of a dynamic
light scattering (DLS) signal.
10. The method of claim 9, comprising: (i) rejecting low frequency
components of the detected DLS signal by using high-pass filters;
and (ii) processing high frequency components to eliminate motion
artifacts.
11. An optical method for use in determining in vivo
hemorheological chemical and physiological parameters of a subject,
the method comprising: (i) applying partially or entirely coherent
light to a target region in said subject to cause a light response
signal from the target region; (ii) detecting fluctuation dependent
speckle pattern of the light response signal over a predetermined
frequency interval, and generating data indicative thereof, (iii)
processing the detected data by using temporal autocorrelation
intensity analyzing or power spectrum analyzing; and, (iv)
determining at least one desired parameter or condition of said
subject from the time-fluctuation of a dynamic light scattering
(DLS) signal, wherein the method comprises creating temporal blood
flow cessation at the measurement region to measure a
post-occlusion signal.
12. The method of claim 11, comprising analyzing the measured
post-occlusion signal to determine blood plasma viscosity.
13. A method of carrying out a non-invasive pulse rate measurement
of a subject having a scattering medium in a target region, said
system comprising: illuminating a target region in said subject by
partially or entirely coherent light so as to cause a light
response signal from the illuminated region; subjecting the light
response signal to a dynamic light scattering measurement (DLS) by
analyzing temporal fluctuations of speckle patterns of the light
response signal; and computing, from the results of analysis of the
temporal fluctuations of the speckle patterns of the DLS
measurement, a pulse rate of the subject, wherein: i. the analysis
includes computing a parameter whose value is approximately
inversely proportional to the shear rate of the flowing blood; and
ii. the pulse rate is derived from the value of the computed
parameter.
14. The method of claim 13 wherein the parameter is the
autocorrelation function decay time parameter.
15. The method of claim 13 wherein the parameter is a decay time
parameter of an autocorrelation function of an intensive of the
light response signal.
16. A method of carrying out a non-invasive pulse rate measurement
of a subject having a scattering medium in a target region, said
system comprising: illuminating a target region in said subject by
partially or entirely coherent light so as to cause a light
response signal from the illuminated region; subjecting the light
response signal to a dynamic light scattering measurement (DLS) by
analyzing temporal fluctuations of speckle patterns of the light
response signal; and computing, from the results of analysis of the
temporal fluctuations of the speckle patterns of the DLS
measurement, a pulse rate of the subject, wherein the analyzing
includes processing the light signal with a band pass filter so as
to compute a power frequency integral upon the frequency interval
having an upper and lower bounds.
17. The method of claim 16 wherein the lower bound of the power
frequency interval is about 2700 Hz.
18. The method of claim 17 wherein the upper bound of the power
frequency interval is about 10,000 Hz.
19. The method of claim 16 wherein the upper bound of the power
frequency interval is about 10,000 Hz.
20. A method of non-invasive in vivo determination of at least one
desired parameter or condition of a subject having a scattering
medium in a target region, the method comprising: illuminating a
target region in said subject by partially or entirely coherent
light so as to cause a light response signal from the illuminated
region, the light response signal having time fluctuations in a
scattering intensity thereof due to changes in distances between
blood particles; detecting time-dependent fluctuations of the
intensity of the light response signal to identify patterns
descriptive of the changes in the distances between blood
particles; generating from the identified patterns, data indicative
of a dynamic light scattering (DLS) measurement; and analyzing the
data indicative of the DLS measurement to determine said at least
one desired parameter or condition, the parameter or condition
being related to the changes in distances between the blood
particles wherein the desired parameter or condition is a systolic
and diastolic blood pressure.
21. An optical method for use in determining in vivo
hemorheological chemical and physiological parameters of a subject,
the method comprising: (i) applying partially or entirely coherent
light to a target region in said subject to cause a light response
signal from the target region; (ii) detecting fluctuation dependent
speckle pattern of the light response signal over a predetermined
frequency interval, and generating data indicative thereof, (iii)
processing the detected data by using temporal autocorrelation
intensity analyzing or power spectrum analyzing; and, (iv)
determining an average size of RBC aggregates of said subject from
the time-fluctuation of a dynamic light scattering (DLS)
signal.
22. An optical method for use in determining in vivo
hemorheological chemical and physiological parameters of a subject,
the method comprising: (i) applying partially or entirely coherent
light to a target region in said subject to cause a light response
signal from the target region; (ii) detecting fluctuation dependent
speckle pattern of the light response signal over a predetermined
frequency interval, and generating data indicative thereof, (iii)
processing the detected data by using temporal autocorrelation
intensity analyzing or power spectrum analyzing; and, (iv)
determining blood coagulation properties of said subject from the
time-fluctuation of a dynamic light scattering (DLS) signal.
23. An optical method for use in determining in vivo
hemorheological chemical and physiological parameters of a subject,
the method comprising: (i) applying partially or entirely coherent
light to a target region in said subject to cause a light response
signal from the target region; (ii) detecting fluctuation dependent
speckle pattern of the light response signal over a predetermined
frequency interval, and generating data indicative thereof, (iii)
processing the detected data by using temporal autocorrelation
intensity analyzing or power spectrum analyzing; (iv) creating
temporal blood flow cessation at the measurement region to measure
a post-occlusion signal and, (v) determining a rate of RBC
aggregation of said subject from the time-fluctuation of a dynamic
light scattering (DLS) signal by analyzing the measured
post-occlusion signal to determine a rate of RBC aggregation.
Description
FIELD OF THE INVENTION
The present invention relates to a system and method for in vivo
measurement of biological parameters of a subject.
BACKGROUND OF THE INVENTION
Near infrared spectroscopy (NIRS) is a well-established
non-invasive technique which allows for the determination of tissue
and blood analytes conditions based on spectrophotometric
measurements in the visible and near-infrared regions of the
spectrum of light. According to this technique, incident light
penetrates the examined skin, and reflected and/or transmitted
light is/are measured. In order to quantify any blood analyte,
light of at least two different wavelengths is required. Optical
plethysmography, pulse oximetry, and occlusion spectroscopy are the
most prominent examples of usage of the NIR spectroscopy in
medicine and physiological studies.
Visible or near infrared light is commonly used to track the
optical manifestation of some time-dependent physiological
processes. Such prolonged measurement of light response as a
function of time can provide clinician with valuable information
about time-dependent physiological processes.
For example, the measured light response of a natural heart beat
pulsation is varied with each pulse. The signal is then measured at
one point of the pulse wave and compared with the signal at another
point. The difference between the values is due to arterial blood
alone. In the pulse-oximetry, this phenomenon is utilized for the
determination of oxy-hemoglobin saturation.
In the case of occlusion spectroscopy, the optical time-dependent
signal is originated by light scattering changes associated with
the red blood cells (RBC) aggregation process. In this case, the
optical signal changes are utilized for the hemoglobin or glucose
measurement.
Yet another known method enables to generate the required changes
is the application of a periodic or non-periodic local pressure
variation, resulting in blood volume fluctuations. These
fluctuations are used to measure different blood parameters, like
hemoglobin or glucose.
The major underlying assumption in the processing of all kind of
the time-dependent signals is that the measured optical variation
is originated solely by blood related components. In pulse
oximetry, for example, it's commonly accepted that arterial blood
volume changes are the only responsible factor staying behind the
optical signal modulation. However, a more complex physical
analysis shows that even if the only changes in the system are
ascribed to the blood, the measured optical response of these
changes is a convolution of absorption and scattering properties of
blood and surrounding media. While carrying out any algorithmic
modeling and signal processing procedure of these measured optical
signals, the tissue related effects can not be disregarded.
Therefore, the common denominator of all time-dependent signal
related optical methods relies on the measurement of optical
responses originated by the blood dynamics or hemorheological
status changes.
It should be noted that the accuracy of time-dependent methods
depends on the ability to identify the hemorheological component of
the blood. For example, in the particular case of pulse-oximetry,
the heart beats modulate the hemorheological status of circulating
blood, resulting in the fluctuation of RBC velocity, which is
associated with the shear forces changes. The variation of the
hemorheological blood parameters enables to optically distinguish
the pulse-related changes of the signal. Therefore, the decreased
accuracy in the determination of hemorheological properties leads
to a lower accuracy in the determination of the sought blood
parameter. Among the blood parameters which can be derived from the
hemorheological changes are hemoglobin oxygen saturation,
carohyhemoglobin (percentage of HbCO out of total hemoglobin),
hemoglobin blood concentration and/or glucose.
Moreover, the arterial blood pressure is another physiological
parameter, which is commonly derived from the hemorheological
related variations. The systolic blood pressure can be determined
with assistance of inflating cuff which induces hemorheological
variations artificially. When a pressure beyond the systolic
pressure is applied, no pulsatile waveform appears at the
down-flow. The diastolic point of the pressure is frequently
measured by using Korotkoff's sounds. The source of these sounds is
associated with abrupt changes in hemorheological properties of
blood, occurring due to deflation of cuff from the systolic point.
These hemorheological changes, in the vicinity of the diastolic
point, result in a very typical pattern of sound, which can be
detected by a stethoscope or by other acoustic device. However, the
sound related method is very sensitive to different motion
artifacts and therefore in automatic blood pressure devices,
commonly used for the self-monitoring, the accuracy of blood
pressure reading is impaired.
SUMMARY OF THE INVENTION
There is a need in the art in facilitating in vivo measurements of
rheological parameters of a subject, by providing a novel
measurement technique. This is associated with the two major
problems related to time-dependent optical methods for the
measurement of hemorheological processes.
Firstly, the method of detecting hemorheological changes optically
has a quite restricted sensitivity. Since the currently used method
of optical measurement detects only scattering or absorption
related changes of the signal, when the aggregation factor not
vary, the scattering and absorption remain unchanged and
hemorheological fluctuations remain unmeasured. For example, the
measured optical signal has few ranges of low sensitivity with
respect to the blood velocity changes. The limitation comes into
force where the blood flow value is very high and, consequently,
RBC aggregation process is prevented by very strong shear forces.
Moreover, when the blood flow is very weak and the RBCs have
already aggregated, the blood flow changes can not affect the
aggregation status.
Secondly, in the currently used technique, there is a problem in
the reduction of motion artifacts. Most of the motion artifacts
interfering with time-dependent measurements are removed based on
fact that the characteristic time constants are different from
slow, motion related interferences. When the motion artifacts
characteristic appearance is in the close vicinity to the signal
appearance (for example, 1 Hz of the heart beat interference with
1.1 Hz of the bounce of the running person), the hemorheological
signal is almost undistinguishable from the artifact.
The novel technique of the present invention enables to
differentiate clearly between the blood-originated and
tissue-related signals, reduce the problem of motion artifacts,
determine at least one desired parameter or condition of a subject
such as hemorheological (blood rheology) related parameters, for
example apparent blood and blood plasma viscosity, red blood cells
(RBC) aggregation, blood flow or blood coagulation properties, and
based on these rheological parameters to determine chemical
parameters of blood, such as oxygen saturation, hemoglobin, or
glucose concentrations and physiological system parameters, like
blood pressure and blood flow.
Moreover, there is a need in performing an accurate blood pressure
measurement by measuring hemorheological properties changes
optically, using more robust and noise resistant method.
As indicated above, the conventional techniques remove most of the
motion artifacts interfering with pulse measurements, using
characteristic time constants of heart beats which are different
from slow motion related interferences. However, other types of
motion artifacts interfering with pulse measurements, such as
patient shivering, can not be removed by such techniques. This type
of artifact is indistinguishable from the signal generated by
pulse, due to the analogous characteristic time constants shared
between pulse frequency and the frequency of the body shivering.
Another example of indistinguishable motion artifact is associated
with walking or running activities, where the characteristic
frequencies of the motion pattern may overlap the heart rate
frequency ranges. The last fact is considered as a great obstacle
in utilization of the photoplethysmography or like for the heart
rate measurements during the sport or walking activities.
The present invention solves the above problems by providing a
novel optical technique suitable for the in vivo measurement in a
subject utilizing dynamic light scattering (DLS) approach. More
specifically, the present invention utilizes the effect of DLS for
the measurement of variety of blood related parameters, like
viscosity of the blood and blood plasma, blood flow, arterial blood
pressure and other blood chemistry and rheology related parameters
such as concentration of analyte (e.g. glucose, hemoglobin, etc.),
oxygen saturation etc.
DLS is a well-established technique to provide data on the size and
shape of particles from temporal speckle analysis. When a coherent
light beam (laser beam, for example) is incident on a scattering
(rough) surface, a time-dependent fluctuation in the scattering
property of the surface and thus in the scattering intensity
(transmission and/or reflection) from the surface is observed.
These fluctuations are due to the fact that the particles are
undergoing Brownian or regular flow motion and so the distance
between the particles is constantly changing with time. This
scattered light then undergoes either constructive or destructive
interference by the surrounding particles and within this intensity
fluctuation information is contained about the time scale of
movement of the particles. The scattered light is in the form of
speckles pattern, being detected in the far diffraction zone. The
laser speckle is an interference pattern produced by the light
reflected or scattered from different parts of an illuminated
surface. When an area is illuminated by laser light and is imaged
onto a camera, a granular or speckle pattern is produced. If the
scattered particles are moving, a time-varying speckle pattern is
generated at each pixel in the image. The intensity variations of
this pattern contain information about the scattered particles. The
detected signal is amplified and digitized for further analysis by
using the autocorrelation function (ACF) technique. The technique
is applicable either by heterodyne or by a homodyne DLS setup.
According to one broad aspect of the invention, it provides a
system for use in non-invasive determination of at least one
desired parameter or condition of a subject having a scattering
medium in a target region. The system comprises an illuminating
system including at least one source of partially or entirely
coherent light to be applied to the target region in said subject
to cause a light response signal from the illuminated region; a
detection system including at least one light detection unit
configured for detecting time-dependent fluctuations of the
intensity of the light response and generating data indicative of
the a dynamic light scattering (DLS) measurement; and, a control
system configured and operable to receive analyze the data
indicative of the DLS measurement to determine the at least one
desired parameter or condition, and generate output data indicative
thereof. The data generated by the detection system is indicative
of fluctuation dependent speckle pattern of the light response over
a predetermined frequency interval.
In some embodiments, the control system is configured and operable
for analyzing the received data by using temporal autocorrelation
intensity analyzing or power spectrum analyzing. The control system
may be configured and operable analyze the received data, to reject
low frequency component of the received data, and process high
frequency components of the received data, thereby enabling
elimination of motion artifacts. The control system comprises: a
data acquisition utility responsive to the generated data coming
from the detection system; a modulating utility associated with the
illuminating system; a data processing and analyzing utility for
analyzing data from the data acquisition utility and determine at
least one hemorheological and blood chemical parameter; a memory
utility for storing coefficients required to perform predetermined
calculation by the data processing and analyzing utility, and an
external information exchange utility configured to enable
downloading of the processed information to an external user or to
display it.
According to some embodiments of the invention, the system
comprises a controllably operated pressurizing assembly configured
and operable to affect a change in a blow flow, the control system
comprising a control utility associated with the pressurizing
assembly.
The system may comprise fiber optics for collecting the light
response signal and delivering it to the detection system.
According to some embodiments of the invention, the system having
at least two light sources operable at different wavelength ranges.
The illuminating system is adapted to produce light of red and near
infrared spectral regions, enabling assessment of the arterial
blood oxygen saturation and/or in blood hemoglobin
determination.
The system may be configured and operable to create an intermittent
blood stasis state by applying over systolic blood pressure to the
subject, thereby enabling the determination of red blood cell (RBC)
aggregation.
In some embodiments, at least one light source of the illumination
system is coupled with a polarization unit enabling to create
polarized electromagnetic signal in one preferable direction. An
entrance of at least one of detection units of the detection system
is also coupled with a polarization unit, such that the
polarization unit enables only certain direction of pre-selected
polarized radiation to be detected increasing the signal to noise
ratio.
According to another broad aspect of the invention, the present
invention provides medical tool for carrying out non-invasive
measurement and/or treatment on a patient's body. The medical tool
comprises an illuminating system generating partially or entirely
coherent light to be focused on a target region in the body, and a
detection system configured for detecting time-dependent
fluctuations of the intensity of the light response and generating
data indicative of a dynamic light scattering (DLS)
measurement.
According to yet another aspect of the invention, the present
invention provides an optical method for use in determining in vivo
hemorheological chemical and physiological parameters of a subject.
The method comprises generating a partially or entirely coherent
light; applying the light to a target region in the subject;
detecting fluctuation dependent speckle pattern of the light
response over a predetermined frequency interval and generating
data indicative thereof, processing the detected data by using the
temporal autocorrelation intensity analyzing or the power spectrum
analyzing; and, determining at least one desired parameter or
condition of the subject from the time-fluctuation of a dynamic
light scattering (DLS) signal.
In some embodiments, the method comprises rejecting low frequency
component of the detected DLS signal by using high-pass filters;
and processing high frequency components to eliminate motion
artifacts.
The chemical parameter comprises at least one of the following: a
blood viscosity, an average size of RBC aggregates, and blood
coagulation properties.
In some other embodiments, the method comprises creating temporal
blood flow cessation at the measurement region to measure a
post-occlusion signal. The method comprises analyzing the measured
post-occlusion signal to determine blood plasma viscosity and a
rate of RBC aggregation.
In some other embodiments, the method comprises illuminating the
target region with light of red and near infrared spectra, thereby
enabling for measuring simultaneously the DLS signal at two or more
wavelengths to determine at least one of the following: arterial
blood oxygen saturation, blood hemoglobin concentration, and
glucose concentration.
According to yet another aspect of the invention, the present
invention provides an optical method for determining in vivo
arterial blood pressure of a subject. The method comprises applying
partially or entirely coherent light to a target region in the
subject to cause a light response signal from the target region;
applying a controllable pressure to the subject so as to induce
hemorheological variations artificially; detecting fluctuation
dependent speckle pattern of the light response signal over a
predetermined frequency interval and generating data indicative
thereof, processing the detected data by using temporal
autocorrelation intensity analyzing or power spectrum analyzing;
and, determining systolic and diastolic arterial blood pressure
values from the time-fluctuation of the DLS signal.
According to yet another aspect of the invention, the present
invention provides an optical method for determining in vivo heart
pulse rate of a subject. The method comprises applying a partially
or entirely coherent light to a target region in the subject to
cause a light response signal from the target region; detecting
fluctuation dependent speckle pattern of the light response over a
predetermined frequency interval, and generating data indicative
thereof; processing the detected data by using temporal
autocorrelation intensity analyzing or power spectrum analyzing;
and, determining the heart rate pulsation from the heart beat time
fluctuation of the DLS related parameter.
The above and other features of the invention including various
novel details of construction and combinations of parts, and other
advantages, will now be more particularly described with reference
to the accompanying drawings and pointed out in the claims. It will
be understood that the particular method and device embodying the
invention are shown by way of illustration and not as a limitation
of the invention. The principles and features of this invention may
be employed in various and numerous embodiments without departing
from the scope of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
In the accompanying drawings, reference characters refer to the
same parts throughout the different views. The drawings are not
necessarily to scale; emphasis has instead been placed upon
illustrating the principles of the invention. Of the drawings:
FIG. 1 is an illustration of a DLS measurement based system
according to the teachings of the present invention;
FIG. 2 is a schematic illustration of a simultaneous measurement of
the transmission signal using photodetector D2 and of the
reflection signal using photodetector D1;
FIG. 3 is a schematic illustration of the use of an optical
fiber-based system;
FIG. 4 is a graphical illustration of a raw data of pulse being
collected and measured from the finger tip by the DLS system;
FIG. 5 is a graphical illustration of a change of a normalized
function at measurement onset (0.5 sec) and after 20 sec of over
systolic occlusion as measured on the finger tip by the DLS;
FIG. 6 is a logarithmic scale graphical presentation of the
same;
FIG. 7 is a graphical presentation of the power spectrum used to
process the measured signal by using a standard Fast Fourier
Transformation (FFT) digital signal processing algorithm;
FIG. 8 is a graphical presentation of the time variation of the
full integral of the power spectrum during an 80 sec duration
measurement section, which is presented in terms of the energy
power spectrum;
FIG. 9 is a graphical presentation of the time variation of the
full integral of the power spectrum during the first 10 seconds of
the pulsatile signal;
FIG. 10 is a graphical presentation of the power spectrum integral
upon the frequency interval [0-550 Hz];
FIG. 11a-b are graphical presentations of the power spectrum
integral upon the frequency interval [2700-10000 Hz];
FIG. 12 is a graphical presentation of the power spectrum integral
upon the frequency interval [1-1.6 KHz];
FIG. 13a is a graphical presentation of the power spectrum integral
in the post-occlusion pulsatile sessions (80-86 sec) upon the
frequency interval [0-2150 Hz];
FIG. 13b is a graphical presentation of the power spectrum integral
in the post-occlusion pulsatile sessions (80-86 sec) upon the
frequency interval [2700-10000 Hz];
FIG. 14 is a graphical presentation of the pulsatile and post
occlusion signals presented in terms of A(tn) and B(tn) of
polynomial coefficients;
FIG. 15 is a graphical presentation of a DLS related parameter
(d(ln(G)/dt)) utilized for the determination of systolic and
diastolic blood pressure;
FIG. 16 is an imaging of a laser temporal speckle contrast K.sub.t
inside occluded blood vessels;
FIG. 17 is an imaging of a laser temporal speckle contrast K.sub.t
inside occluded blood vessels and laser irradiation;
FIG. 18 is a graphical presentation of a DLS measurement utilized
for the determination of the oxygen saturation changes; and,
FIG. 19 is a graphical presentation of the measured pulsatile
component of the blood in terms of d(ln(AUT)/d.tau..
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Reference is made to FIG. 1 illustrating a DLS measurement based
system 100 implementing the present invention. System 100 includes
a light source unit 10 (e.g. laser) for generating at least
partially coherent light; optical arrangement (not shown) including
focusing optics and possibly also collecting optics; and a
detection unit 16. A focused beam of light 12 produced by laser 10
(e.g., a He--Ne laser) is used as a localized light source. In a
non-limiting example, a light source unit 10 may be a laser diode
(650 nm, 5 mW) or VCSEL (vertical cavity surface emitting laser).
The light response i.e. the reflected and/or transmitted light
returned from the localized region of the subject's surface 14
(patient's finger in the present example) illuminated with the
localized light source 10, can be collected in a determined
distance L (in a non-limiting example, L=100 mm) either directly by
a detector or via multimode fiber optics. In a non-limiting
example, the multimode fiber optics may be a bifurcated randomized
optical fiber where one optical entrance is connected to the
detector and another one is optically coupled with the laser diode.
In particular, as shown in FIG. 1, system 100 includes at least one
laser diode 10 and at least one photodetector (photodiodes) 16
appropriately positioned in the reflection-mode measurement
set-up.
As exemplified in FIG. 2, the system may be operable to implement
simultaneous measurement of the transmission signal using
photodetector D2 and reflection signal using photodetector D1. This
can be used for a relatively transparent (for the respective
wavelength range) subject (i.e. like through a subject's finger tip
14). It should be noted that generally, the system may be operable
in either one of transmission and reflection modes or both of
them.
FIG. 3 exemplifies the use of an optical fiber-based system 200
having a somewhat different configuration. One of the advantages of
optical fiber-based system 200 lies in the maximum flexibility of
such system for non-invasive measurement of subjects. The use of
randomized optical fiber secured geometric stability and the small
effective distance between light source 10 and detector 16 is
responsible for a high signal to noise ratio. It should be noted
that the same fiber optic bundle 36 can be used for both the
collection of the signal from the measured subject and the delivery
of the coherent radiation towards the subject to be measured.
Further provided is a control system having an electronic unit 32
and a data processor and analyzer (CPU) 34. The electronic unit 32
is configured and operable to reject a low frequency component of
the detected signal by using high-pass analog filters, and process
only high frequency components to strongly amplify them, digitize
them, and pass to the control unit (CPU) 34 for further digital
processing. This approach enables the required sensitivity and
dynamic range to be increased which is essential to account for
only DLS related component of the measured signal. In a
non-limiting example, the data is collected at 22 KHz sampling rate
and 16-bit resolution.
The kinetics of optical manifestations of two kinds of
physiological signals is measured in vivo: the pulsatile signal
associated with heart beats and the post-occlusion optical signal
which is induced by an artificially generated blood flow cessation.
The light transmission and/or reflection signals are used as a
control of the physiological response. This kind of control
measurement can be carried out simultaneously with the DLS
reflection measurement. The mutual correspondence between DLS and
standard optical signals is subject to a comparison analysis.
The following is an example of analysis of pulsatile and
post-occlusion signals. Reference is made to FIG. 4 showing an
example of raw data of pulse (AC signal variation with time) which
is collected and measured from a finger tip by DLS system 100. The
low frequency components of the signal are rejected by an analog
filter of electronic box 32. Subsequently, the signal is amplified
and digitized for further analysis.
Generally, two standard approaches are commonly applicable to an
analysis of DLS signals. The first approach uses the temporal
autocorrelation of the intensity, and the second approach entails
the analysis of the power spectrum P(w) of the detected signal.
According to the first approach, the formula for the correlation
function G(.tau.) of temporal intensity fluctuations of light
scattered by moving particles is given by:
.function..tau..function..function..tau..function. ##EQU00001##
where I(t) is the intensity at time t and < . . . > denotes
an ensemble average. It has to be taken into consideration that for
preferable configuration of measurement system 100, the intensity
of the signal I(t) already lacks zero and low frequencies
components of the signal (0-100 Hz), which are already removed by
the high-pass analog filter of the electronic box 32.
When the measured signal is converted from an analog to digital
form, the autocorrelation function is calculated by using a
summation, averaging over N sampling points given by the following
expression:
.function..tau..times..times..function. .function..function.
##EQU00002##
FIG. 5 shows a typical example of a normalized function G(.tau.)
change as function of time and over systolic occlusion (20 sec
occlusion vs 0.5 sec onset) as measured on the finger tip by DLS
system 100. For the purpose of the present application, the term
"over systolic occlusion" refers to an application of over systolic
pressure to create a temporary blood flow cessation state at the
measurement location. The first measurement onset (T=0.5 sec)
displays a more fast decrease of G(t) in initial measurement stage
(0-0.001 sec) comparatively to second measurement (T=20 sec)
occlusion data. More moderate time-dependent decrease of G(t) is
noticed for both experiments in more advanced stage (>0.001
sec)
The logarithmic scale presentation of the same represented in FIG.
6 reveals a quasi-exponential nature of function G(.tau.).
According to the second approach, the power spectrum presentation
is used to process the detected signal. The power spectrum of the
measured signal can be constructed by using a standard Fast Fourier
Transformation (FFT) digital signal processing algorithm. FIG. 7
shows an example of the FFT of such a signal. The highest spectral
frequency in the FFT presentation is defined by the number of the
sampling points and the overall measurement time interval. The
total energy of a power spectrum PwS[f1,f2] is bounded in the
frequencies interval (f1, f2) and can be evaluated by a simple
summation. This value can be used as a measure of changes which
occurs during any physiological processes during the blood flow or
during the blood flow cessation.
FIG. 8 shows the time variation of the full integral of the power
spectrum (i.e. energy power spectrum) during an 80 sec duration
measurement section of the pulsatile signal. Each point of the
power spectrum PwS[f1,f2] is calculated for a pre-set time
interval. In this particular example, the interval is 0.0454 sec.
The calculated value is normalized:
.function..times..times..times..times..times..times..times..times..times.-
.function..times..times..times..function. ##EQU00003##
FIG. 9 shows the time variation of the full integral of the power
spectrum during the first 10 seconds of the pulsatile signal. The
characteristic behavior of the power spectrum PwS depends upon the
frequency interval f1,f2. For example, referring to FIGS. 10 and
11a-b, the function defined by PwS [0,550 Hz] (t) for the frequency
window [0,550 Hz], behaves differently as compared to PwS [2700,
10000 Hz] (FIG. 11a-b). Strong dependence of PwS function upon the
chosen frequencies parameters is confirmed for the pulsatile phase,
as illustrated in FIG. 11a and FIG. 11b. At a predetermined a
frequency interval, PwS behaves as a very weak function of ongoing
physiological scattering changes, as illustrated in FIG. 12. In
this particular example, this interval is identified as being
located at approximately the frequency interval [1-1.6 kHz]. This
interval is defined as the critical frequency point (CFP), which
can be related to the parameters of the autocorrelation
function.
According to the statements of the Wiener-Khinchin theorem, PwS
density of a wide-sense-stationary random process is the Fourier
Transform of the corresponding autocorrelation function. Since the
autocorrelation function is an even function, the classic Fourier
integral is reduced to:
.function..omega..apprxeq..intg..infin..times.
.pi..times..function..omega. .tau. .function..tau. .times.d.tau.
##EQU00004##
For a very simple case, the normalized intensity correlation
function can be approximated to:
g.sub.2(.tau.).apprxeq.exp(-.alpha.*.tau.), where .alpha. is a
factor proportional to the diffusion parameter D.
After the integration of the expression, [4] reduces to:
.apprxeq..alpha..alpha..omega. ##EQU00005##
In order to find the minimum point of P, the differentiation of g
with respect to .alpha. is taken:
.function..times..times..alpha..alpha..omega..alpha..omega.
.times..times..alpha. ##EQU00006##
Therefore, for P(t)=0,.omega.=.alpha. [7]
According to this expression, CFP can be used to evaluate the
diffusion parameter D.
The post-occlusion pulsatile sessions (80-86 sec) are represented
for the frequency window [0, 2150 Hz] in FIG. 13a, and for the
frequency window [2700, 10000 Hz] in FIG. 13b.
Thus, the invented technique provides for using DLS for measurement
of various parameters of a subject, particularly blood analytes. In
this connection, it should be noted that the multiple scattering
predominates the light propagation through the blood and tissue.
This is why the transport approximation is considered to be a more
appropriate approach for the invented technique.
In the case of DLS, the measured parameter is autocorrelation
function g.sub.1. For an infinite medium with a point source, this
parameter can be approximated by: g.sub.1(.tau.)=exp(- {square root
over
(k.sub.0.sup.2*<.DELTA.r.sup.2(.tau.)>+3.mu..sub..alpha.l)}*(r.sub.-
sd/l) [8] where <r.sup.2(.tau.)>=6D.tau. is the mean squared
displacement of the scattered particles, l is mean free path of
light and D is the diffusion coefficient given by Stoke-Einstein
relation.
.pi..eta..times..times. ##EQU00007## Substitution of K and D into
[8] gives:
.function..tau..lamda..times..times..pi..times..times..lamda.
.pi..eta..times..times..times..mu. ##EQU00008##
It should be pointed out that .mu..sub..alpha. is a function of
light absorption dependent on the hemoglobin concentration and
blood oxygen saturation level in blood. This expression can be used
to process the DLS measurement of aggregation driven post-occlusion
measurement where the Brownian motion takes over.
The value g.sub.1 relates to the measured autocorrelation function
by the Segert relation: g.sub.2(.tau.)=1+.beta.*|g.sub.1|.sup.2
[11]
In the case of a free pulsatile signal, the blood flow related
phenomena are dominated by fluctuations of blood cells with a major
contribution of red blood cells (RBC).
The autocorrelation function decay is governed by the velocity
variations measured across the blood vessels. If V(L) is the
standard deviation of velocity difference across the source width
L, then decay time is defined by:
.tau..apprxeq..function. ##EQU00009##
The velocity difference of flowing blood is a function of its shear
rate. This rate depends on variety of rheological parameters, such
as blood viscosity or the actual size of flowing particles. Single
RBC tends to form aggregates that can reversibly disaggregate under
the influence of shear forces; RBC aggregation is a major
determinant of the shear-thinning property of blood.
In a vessel of radius R, axisymmetric velocity profiles v(r,t) can
be described in cylindrical coordinates by the empirical
relationship: v(r,t).apprxeq.v.sub.max*(1-(r/R).sup..xi.)*f(t) [13]
where -1<(r/R)<1,f(t) is a periodic function of heart beat
frequency, which is driven by systolic pressure wave and it is time
phase-shifted with respect to the cardiac cycle, and .xi.
represents the degree of blunting. For example, in 30 micron
arterioles, there is a range of .xi.2.4-4 at normal flow rates. If
.xi.=2, a parabolic velocity distribution is obtained. Blunting
would occur even in larger arterioles at low flow rates. By using
the expression for d(v(r,t)) the standard deviation d(v) can be
calculated by:
.function. .function..times..intg..function. d.intg..function.
d.xi. .xi. .function. ##EQU00010##
For small arterials (around 20 microns), the fluctuation of
velocity from systolic to diastolic phases ranges from 1.5 mm/s to
2.5 mm/s. This results in a very significant fluctuation of
standard deviation (rms) during the systolic-diastolic cycle.
Pulsatile signal, therefore, can be used for calculation of
hemorheological parameters. The DLS related pulsatile signal is
advantageous over regular pulse measurement where the motion
artifacts are prevalent. In addition, it should be noted that
hemorheological changes can be extracted optically even if the
scattering or absorption related changes are negligible.
Therefore two major benefits are achieved: first, the pulsatile or
other hemorheological change can be measured optically by using
DLS-related technique; secondly, due to the process of only high
frequency components in the DLS approach, low frequency
interference is therefore eliminated, also eliminating motion
artifacts.
Another hemorheological parameter relates to the blood plasma
viscosity. The post-occlusion signal (which is achieved during the
stasis stage) can be utilized to evaluate blood plasma viscosity.
In this case, the particles are displaced in the blood by Brownian
motion according to the Stoke-Einstein equation [9].
It is clear that for the post-occlusion signal, the observed
changes in the DLS signal are driven by the growth rate of d(t),
following the growth of RBC aggregate size. The rate of RBC
aggregate growth can be defined by calculating the change of
autocorrelation function occurring during the stage of blood flow
cessation (post-occlusion stage). Therefore the rate of RBC
aggregation can be measured by using this technique.
If the DLS signal is measured simultaneously at two or more
wavelengths, then by using equation [10] or other such equations,
the most influential scattering or absorption related parameters,
such as oxygen blood saturation, hemoglobin or glucose can be
determined since absorption properties of the scattering particles
affect the DLS related parameters [10].
If the measurement system (e.g. system 100) includes a controllable
pressurizing assembly, then the DLS effect can be used for
measurement of arterial blood pressure. The point of systolic
pressure is easily identified as a point of disappearance of the
pulsatile signal, which is monitored either in terms of
autocorrelation parameters or in terms of power spectrum. When the
arterial pressure exceeds the cuff pressure, blood squirts through
the partially occluded artery and creates turbulence, which creates
the well-known Korotkoff sounds. Effect of turbulence results in
dramatic change in fluctuation dependent speckle pattern which is
expressed in an instant change of DLS parameters.
In many applications ln(G(.tau.)) can be approximated by a
polynomial form: G(.tau.)=A.tau..sup.2+B.tau.+C [15]
FIG. 14 illustrates how the pulsatile and post occlusion signals
can be presented in terms of polynomial coefficients A and B being
defined in terms of autocorrelation analysis. In this example, the
measurement session includes few physiological stages: a) an
initial pulsatile signal session, b) an arterial blood occlusion
session, and c) a pulsatile signal session after release of the
over systolic (occlusion) session, all over the measurement
duration of 80 seconds.
FIG. 15 shows the behavior of a DLS related parameter (d(ln(G)/dt))
utilized for the determination of systolic and diastolic blood
pressure. In this experiment, the pressurizing cuff is inflated up
to over systolic pressure of 200 mm Hg during the first 5 seconds.
Thereafter, for the next 75 seconds, the air pressure in the cuff
is gradually reduced. Simultaneously, the DLS measurement is
carried out at the area beneath the cuff. It is clearly seen in
FIG. 15, that the parameter d(Ln(G))/dt reaches its minimum point
when the pressure measured in the cuff gets equal to the systolic
pressure, as was defined previously by doing a standard blood
pressure measurement test. Moreover, at the moment where the
pressure in the cuff exceeds previously defined systolic pressure
point, exactly at this point the value of parameter d(Ln(G))/dt
starts to increase gradually. Therefore, by identifying these two
extreme points on the curve of d(Ln(G))/dt, both systolic and
diastolic blood pressure can be measured optically. Naturally, all
other functions mathematically related to autocorrelation
parameters, can be used for blood pressure measurement.
This very unique sensitivity of DLS related parameters to the blood
flow can be used for identification of blood flow disturbances or
even for blood stasis identification and verification. To this end,
any kind of a medical tool such as intro-vascular catheter (e.g.
used for angioplasty) can be linked with DLS equipped optical
fiber. Such a system is very efficient for identification of plugs
and blood vessels abnormalities disturbing the normal blood
flow.
Moreover, blood circulation parameters measured by DLS technique
can by embedded as an inherent part of new emerging technology of
biofeedback. Based upon the biofeedback technique, different body
parameters including the blood flow that can be beneficial to
control emotional status, cardiovascular training, rehabilitation
and other purposes can be controlled. For example, such a system
can be used for the control of blood flow during recovery from
heart failure. In the biofeedback applications, DLS based
measurement system can be combined with facilities affecting the
mental status of a subject. For example, a method of binaural beats
can be used. The binaural beats are resulted from the interaction
of two different auditory impulses, originating in opposite ears.
The binaural beat is not heard but is perceived as an auditory beat
and theoretically can be used to entrain specific neural rhythms
through the frequency-following response (FFR), i.e. the tendency
for cortical potentials to entrain to or resonate at the frequency
of an external stimulus. Thus, a consciousness management technique
can be utilized to entrain a specific induction of sympathetic and
parasympathetic system. More specifically, biofeedback system based
on the methods of binaural beats can be governed by the parameters
of flowing blood measured by means of DLS.
There is also provided a method to select appropriate frequencies
characteristics of the binaural beats, according to the
optimization curve of peripheral blood parameters, which are
tightly associated with a stage of maximum relaxation.
EXAMPLES
Various examples were carried out to prove the embodiments claimed
in the present invention. Some of these experiments are referred
hereinafter. The examples describe the manner and process of the
present invention and set forth the best mode contemplated by the
inventors for carrying out the invention, but are not to be
construed as limiting the invention.
Example 1
To develop an optimized experimental approach for noninvasive
visualization of blood clotting in vivo, an experimental protocol
which allows visualizing fine changes in RBC motion at high spatial
and temporal resolution, deep inside the tissue was
established.
The experiments were performed on occluded blood vessels and
detection was carried out by modification of DLS described above.
Anesthetized animal (nude mice) were placed on the stage of a setup
for intravital microscopy. Temporal over systolic occlusion was
created by using a mechanical occluder which produces local
mechanical pressure on the area of visibly large arteries within
the mouse ear. The duration of the occlusion did not exceed 10
minutes.
In the first set of experiments, the illuminated area was imaged
via a microscope by a CCD camera. The exposure time T of the CCD
was 50 ms. Images were acquired through easy-control software at 20
Hz. The optical design of the system allowed for simultaneous laser
irradiation and observation of a process of blood clotting via
usage of a short pass optical filter (450 nm) placed in front of
the CCD camera.
It was observed that mechanical occlusion of major blood vessels
never leads to complete blood flow stasis in microvessels. Even
after maximal occlusion, RBCs continued to move and the character
of such motions was not stochastic. RBCs were moving for up to 1
hour after animals were euthanatized. Therefore the absence of RBC
motion in an occluded vessel can be a sign of blood clotting in
vivo since polymerized fibrin can prevent even minimal movements of
RBCs.
Example 2
In order to monitor the blood clotting process, as well as to solve
the problem of light scattering by skin and tissue, DLS from laser
light was used for imaging the fine changes in RBC motion inside
occluded vessels through the skin of the mouse ear. Particularly in
the second set of experiments, the same animal model and procedures
for animal care as described above were used.
A diode laser (670 nm, 10 mW) was coupled with a diffuser, which
was adjusted to illuminate the area of a mouse ear. The illuminated
area was imaged through a zoom stereo microscope by a CCD camera.
The exposure time T of the CCD was 50 ms. Images were acquired
through easy-control software at 20 Hz. DLS imaging of RBC motion
in occluded microvessels was based on the temporal contrast of
intensity fluctuations produced from laser speckles that reflected
from mouse tissue.
The temporal statistics of time integrated speckles was utilized in
order to obtain a two-dimensional velocity map which represents
blood vessels under flow and no-flow conditions. The value of the
laser temporal contrast K.sub.t at pixel (x,y) was calculated based
on the following formula:
K.sub.t(x,y)=.sigma..sub.x,y/I.sub.x,y
Where I.sub.x,y(n) is the CCD counts at pixel (x,y) in the n.sup.th
laser speckle image, N is the number of images acquired and
I.sub.x,y is the mean value of CCD counts at pixel (x,y) over the N
images.
Temporal mechanical blood occlusion in the observed area was
applied, as described before, to ensure blood flow cessation.
Referring to FIG. 16, the laser temporal speckle contrast K.sub.t
was higher (intensity scale 0-1 in the right side of the image
refers the value of laser speckle temporal contrast) inside
occluded blood vessels in which RBC motion can be detected. These
vessels are represented by "white" pattern while the darker areas
are referred to the blood vessels in which RBC motion was low or
negligible.
In addition, two minutes after occlusion, the beam of a Diode
Pumped Solid State (DPSS) laser module, (Laser-Glow, Canada, 532
nm, 100 mW) was directed (at an angle of 45 degrees or less) onto
the ear of an anesthetized mouse. The laser was focused in order to
create a pinpoint injury on the mouse ear (200 .mu.m). The injury
was induced with a short high intensity laser burst and laser
injury was induced at the area indicated by white arrows in frames
15s and 20s. The "white" pattern of blood vessels during DLS
imaging, as illustrated in FIG. 17 of occluded blood vessels in the
mouse ear can be related to remaining RBC motion. Conversely,
relative changes in the intensity of K.sub.t upon clotting can be
caused by elevation of blood/plasma viscosity as a result of blood
clotting.
In the experiments, two elements of Virchow's triad were used to
induce the process of clotting in vivo and to assess it optically.
Both changes in the vessel wall, as well as in the pattern of blood
flow, predispose the area to vascular thrombosis and blood
clotting. Thus, DLS images generated by RBC motion inside occluded
blood vessels as a marker of the blood clotting process in vivo
were used.
Example 3
In order to monitor the change of oxygen saturation, a DLS system
having two light sources was used. The light sources have
respectively a wavelength of 650 nm and 810 nm. Absorption at these
wavelengths differs significantly between oxyhemoglobin and its
deoxygenated form, therefore from the ratio of the absorption of
the red and infrared light the oxy/deoxyhemoglobin ratio can be
calculated. The ratio of the two autocorrelation parameter (R1, R2)
for each wavelength was measured. The patient was asked to hold hit
breath for approximately 30 seconds. As illustrated in FIG. 18, the
oxygen saturation drops. Then, the breath was reactivated,
illustrated by a restoration of the oxygen saturation. The graph
demonstrates the behavior of ratio of R1/R2 during this experiment
and reveals good correspondence between the ratio and the induced
change of oxygen saturation.
Example 4
By using the DLS related technique of the present invention, heart
rate can also be measured. In this experiment, the method was
tested on an upper wrist. This particular area is considered as a
hardly available area for the commonly used photoplethysmographic
method of pulse measurement. The pulsatile component in the wrist
area is very weak and therefore is not used nor for heart rate
measurement neither for pulse oximetry.
A special probe including a coherent light source (VCSEL (vertical
cavity surface emitting laser) of 820 nm), a detection unit, a
laser driver and a preamplifier probe was constructed. The
detection unit was located in close vicinity of the light source.
All this system was encapsulated in the enclosure having a
wristwatch form. This "wristwatch" was closely attached to the
wrist and the measurement has been carried out. The DLS signal
reflected from the skin area has been detected, amplified and
digitized at the rate of 40 KHz. The obtained results have been
processed. The auto-correlation function (AUT) was determined and
averaged over 0.05 sec and the slope of the logarithm of AUT as a
function of .tau. (sampling rate) was calculated.
(d(ln(AUT)/d.tau.)).
FIG. 19 represents the measured pulsatile component of the blood in
terms of d(ln(AUT)/d.tau.. Heart rate is extracted from the
obtained signal by utilizing any of commonly used methods such as
FFT method.
While this invention has been particularly shown and described with
references to preferred embodiments thereof, it will be understood
by those skilled in the art that various changes in form and
details may be made therein without departing from the scope of the
invention encompassed by the appended claims.
* * * * *